Skip to main content
Top
Published in: BMC Psychiatry 1/2021

Open Access 01-12-2021 | Schizophrenia | Research

Predicting time to relapse in patients with schizophrenia according to patients’ relapse history: a historical cohort study using real-world data in Sweden

Authors: Kristian Tore Jørgensen, Martin Bøg, Madhu Kabra, Jacob Simonsen, Michael Adair, Linus Jönsson

Published in: BMC Psychiatry | Issue 1/2021

Login to get access

Abstract

Background

For patients with schizophrenia, relapse is a recurring feature of disease progression, often resulting in substantial negative impacts for the individual. Although a patient’s relapse history (specifically the number of prior relapses) has been identified as a strong risk factor for future relapse, this relationship has not yet been meticulously quantified. The objective of this study was to use real-world data from Sweden to quantify the relationship of time to relapse in schizophrenia with a patient’s history of prior relapses.

Methods

Data from the Swedish National Patient Register and Swedish Prescribed Drug Register were used to study relapse in patients with schizophrenia with a first diagnosis recorded from 2006–2015, using proxy definitions of relapse. The primary proxy defined relapse as a psychiatric hospitalisation of ≥7 days’ duration. Hazard ratios (HRs) were calculated for risk of each subsequent relapse, and Aalen-Johansen estimators were used to estimate time to next relapse.

Results

2,994 patients were included, and 5,820 relapse episodes were identified using the primary proxy. As the number of previous relapses increased, there was a general trend of decreasing estimated time between relapses. Within 1.52 years of follow-up, 50% of patients with no history of relapse were estimated to have suffered their first relapse episode. 50% of patients with one prior relapse were estimated to have a second relapse within 1.23 years (HR: 1.84 [1.71–1.99]) and time to next relapse further decreased to 0.89 years (HR: 2.77 [2.53–3.03]) and 0.22 years (HR: 18.65 [15.42–22.56]) for 50% of patients with two or ten prior relapses, respectively. Supplementary analyses using different inclusion/exclusion criteria for the study population and redefined proxies of relapse reflected the pattern observed with the primary analyses of a higher number of prior relapses linked with increased risk of/reduced estimated time to the next relapse.

Conclusions

The results suggested a trend of accelerating disease progression in schizophrenia, each relapse episode predisposing an individual to the next within a shorter time period. These results emphasise the importance of providing early, effective, and tolerable treatments that better meet a patient’s individual needs.
Appendix
Available only for authorised users
Literature
1.
go back to reference National Institute for Health and Care Excellence [NICE]. Psychosis and schizophrenia in adults: prevention and management. National Institute for Health and Care Excellence (NICE). 2014;NICE Guideline 178. National Institute for Health and Care Excellence [NICE]. Psychosis and schizophrenia in adults: prevention and management. National Institute for Health and Care Excellence (NICE). 2014;NICE Guideline 178.
2.
go back to reference Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–59.CrossRef Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–59.CrossRef
3.
go back to reference Olivares JM, Sermon J, Hemels M, Schreiner A. Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review. Ann Gen Psychiatry. 2013;12(1):32.CrossRef Olivares JM, Sermon J, Hemels M, Schreiner A. Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review. Ann Gen Psychiatry. 2013;12(1):32.CrossRef
4.
go back to reference Taylor M, Chaudhry I, Cross M, McDonald E, Miller P, Pilowsky L, et al. Towards consensus in the long-term management of relapse prevention in schizophrenia. Hum Psychopharmacol. 2005;20(3):175–81.CrossRef Taylor M, Chaudhry I, Cross M, McDonald E, Miller P, Pilowsky L, et al. Towards consensus in the long-term management of relapse prevention in schizophrenia. Hum Psychopharmacol. 2005;20(3):175–81.CrossRef
5.
go back to reference Kane JM. Treatment strategies to prevent relapse and encourage remission. J Clin Psychiatry. 2007;68:27–30.CrossRef Kane JM. Treatment strategies to prevent relapse and encourage remission. J Clin Psychiatry. 2007;68:27–30.CrossRef
6.
go back to reference Almond S, Knapp M, Francois C, Toumi M, Brugha T. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry. 2004;184(4):346–51.CrossRef Almond S, Knapp M, Francois C, Toumi M, Brugha T. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry. 2004;184(4):346–51.CrossRef
7.
go back to reference Pennington M, McCrone P. The cost of relapse in schizophrenia. Pharmacoeconomics. 2017;35(9):921–36.CrossRef Pennington M, McCrone P. The cost of relapse in schizophrenia. Pharmacoeconomics. 2017;35(9):921–36.CrossRef
8.
go back to reference Robinson D, Woerner MG, Alvir JMJ, Bilder R, Goldman R, Geisler S, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241–7.CrossRef Robinson D, Woerner MG, Alvir JMJ, Bilder R, Goldman R, Geisler S, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56(3):241–7.CrossRef
9.
go back to reference Goff DC, Hill M, Freudenreich O. Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2010;71:20–6.CrossRef Goff DC, Hill M, Freudenreich O. Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2010;71:20–6.CrossRef
10.
go back to reference DiBonaventura M, Gabriel S, Dupclay L, Gupta S, Kim E. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC psychiatry. 2012;12(1):20. DiBonaventura M, Gabriel S, Dupclay L, Gupta S, Kim E. A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia. BMC psychiatry. 2012;12(1):20.
11.
go back to reference Tiihonen J, Mittendorfer-Rutz E, Majak M, Mehtälä J, Hoti F, Jedenius E, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry. 2017;74(7):686–93.CrossRef Tiihonen J, Mittendorfer-Rutz E, Majak M, Mehtälä J, Hoti F, Jedenius E, et al. Real-world effectiveness of antipsychotic treatments in a nationwide cohort of 29 823 patients with schizophrenia. JAMA Psychiatry. 2017;74(7):686–93.CrossRef
12.
go back to reference Ascher-Svanum H, Zhu B, Faries DE, Salkever D, Slade EP, Peng X, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC psychiatry. 2010;10(1):2. Ascher-Svanum H, Zhu B, Faries DE, Salkever D, Slade EP, Peng X, et al. The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC psychiatry. 2010;10(1):2.
13.
go back to reference Ascher-Svanum H, Novick D, Haro JM, Bertsch J, McDonnell D, Detke H. Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind study. BMC psychiatry. 2013;13(1):224. Ascher-Svanum H, Novick D, Haro JM, Bertsch J, McDonnell D, Detke H. Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind study. BMC psychiatry. 2013;13(1):224.
14.
go back to reference Malla A, Norman R, Bechard-Evans L, Schmitz N, Manchanda R, Cassidy C. Factors influencing relapse during a 2-year follow-up of first-episode psychosis in a specialized early intervention service. Psychol Med. 2008;38(11):1585.CrossRef Malla A, Norman R, Bechard-Evans L, Schmitz N, Manchanda R, Cassidy C. Factors influencing relapse during a 2-year follow-up of first-episode psychosis in a specialized early intervention service. Psychol Med. 2008;38(11):1585.CrossRef
15.
go back to reference Haro JM, Novick D, Suarez D, Alonso J, Lépine JP, Ratcliffe M, et al. Remission and relapse in the outpatient care of schizophrenia: Three-year results from the schizophrenia outpatient health outcomes study. J Clin Psychopharmacol. 2006;26(6):571–8.CrossRef Haro JM, Novick D, Suarez D, Alonso J, Lépine JP, Ratcliffe M, et al. Remission and relapse in the outpatient care of schizophrenia: Three-year results from the schizophrenia outpatient health outcomes study. J Clin Psychopharmacol. 2006;26(6):571–8.CrossRef
16.
go back to reference Lecomte T, Potvin S, Samson C, Francoeur A, Hache-Labelle C, Gagné S, et al. Predicting and preventing symptom onset and relapse in schizophrenia—A metareview of current empirical evidence. J Abnorm Psychol. 2019;128(8):840–54.CrossRef Lecomte T, Potvin S, Samson C, Francoeur A, Hache-Labelle C, Gagné S, et al. Predicting and preventing symptom onset and relapse in schizophrenia—A metareview of current empirical evidence. J Abnorm Psychol. 2019;128(8):840–54.CrossRef
17.
go back to reference Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. NEJM. 2002;346(1):16–22.CrossRef Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. NEJM. 2002;346(1):16–22.CrossRef
19.
go back to reference World Health Organization [WHO]. International Classification of Diseases (10th revision). Geneva: World Health Organization (WHO); 2004. World Health Organization [WHO]. International Classification of Diseases (10th revision). Geneva: World Health Organization (WHO); 2004.
20.
go back to reference World Health Organization [WHO]. International Classification of Diseases (9th revision). Geneva: World Health Organization (WHO); 1978. World Health Organization [WHO]. International Classification of Diseases (9th revision). Geneva: World Health Organization (WHO); 1978.
22.
go back to reference World Health Organization [WHO]. The Anatomical Therapeutic Chemical Classification System: structure and principles. WHO Collaborating Centre for Drug Statistics Methodology. 2018. World Health Organization [WHO]. The Anatomical Therapeutic Chemical Classification System: structure and principles. WHO Collaborating Centre for Drug Statistics Methodology. 2018.
23.
go back to reference Aalen OO, Johansen S. An empirical transition matrix for non-homogeneous Markov chains based on censored observations. Scand Stat Theory Appl. 1978:141–50. Aalen OO, Johansen S. An empirical transition matrix for non-homogeneous Markov chains based on censored observations. Scand Stat Theory Appl. 1978:141–50.
24.
go back to reference Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull. 1991;17(2):325–51.CrossRef Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull. 1991;17(2):325–51.CrossRef
25.
go back to reference Craig TK, Garety P, Power P, Rahaman N, Colbert S, Fornells-Ambrojo M, et al. The Lambeth Early Onset (LEO) Team: randomised controlled trial of the effectiveness of specialised care for early psychosis. BMJ. 2004;329(7474):1067.CrossRef Craig TK, Garety P, Power P, Rahaman N, Colbert S, Fornells-Ambrojo M, et al. The Lambeth Early Onset (LEO) Team: randomised controlled trial of the effectiveness of specialised care for early psychosis. BMJ. 2004;329(7474):1067.CrossRef
26.
go back to reference McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67–76.CrossRef McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol Rev. 2008;30:67–76.CrossRef
27.
go back to reference Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, et al. Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. Schizophrenia Bulletin. 2018;44(6):1195–203.CrossRef Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, et al. Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. Schizophrenia Bulletin. 2018;44(6):1195–203.CrossRef
28.
go back to reference Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLOS Medicine. 2005;2(5):e141.CrossRef Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia. PLOS Medicine. 2005;2(5):e141.CrossRef
29.
go back to reference Jönsson L, Simonsen J, Brain C, Kymes S, Watson L. Identifying and characterizing treatment-resistant schizophrenia in observational database studies. Int J Methods Psychiatr Res. 2019;28(3):e1778.CrossRef Jönsson L, Simonsen J, Brain C, Kymes S, Watson L. Identifying and characterizing treatment-resistant schizophrenia in observational database studies. Int J Methods Psychiatr Res. 2019;28(3):e1778.CrossRef
30.
go back to reference Jeppesen RM, Christensen T, Vestergaard CH. Changes in the utilization of psychiatric hospital facilities in Denmark by patients diagnosed with schizophrenia from 1970 through 2012. Acta Psychiatr Scand. 2016;133(5):419–25.CrossRef Jeppesen RM, Christensen T, Vestergaard CH. Changes in the utilization of psychiatric hospital facilities in Denmark by patients diagnosed with schizophrenia from 1970 through 2012. Acta Psychiatr Scand. 2016;133(5):419–25.CrossRef
31.
go back to reference Kane JM, Schooler NR, Marcy P, Correll CU, Achtyes ED, Gibbons RD, et al. Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2020;77(12):1217–24.CrossRef Kane JM, Schooler NR, Marcy P, Correll CU, Achtyes ED, Gibbons RD, et al. Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2020;77(12):1217–24.CrossRef
Metadata
Title
Predicting time to relapse in patients with schizophrenia according to patients’ relapse history: a historical cohort study using real-world data in Sweden
Authors
Kristian Tore Jørgensen
Martin Bøg
Madhu Kabra
Jacob Simonsen
Michael Adair
Linus Jönsson
Publication date
01-12-2021
Publisher
BioMed Central
Keyword
Schizophrenia
Published in
BMC Psychiatry / Issue 1/2021
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/s12888-021-03634-z

Other articles of this Issue 1/2021

BMC Psychiatry 1/2021 Go to the issue